Clinical trial NCT03340233: Understanding the Mechanisms of Diastolic Dysfunction
Official title: A New Framework for Understanding the Mechanism of Diastolic Dysfunction
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Heart Failure With Preserved Ejection Fraction
Healthy
Keywords: diastolic dysfunction
mechanism
MRI magnetic resonance imaging
ejection fraction
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2017-11-13
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Heart failure is a clinical syndrome marked by breathlessness, even at low levels of exertion, general fatigue, and fluid retention and is estimated to affect 5.1 million people in the United States. Heart failure with preserved ejection fraction (HFpEF) means that the heart pumps enough blood to the body, but patients still have terrible symptoms. It is estimated to account for about 50% of all heart failure cases. Experts agree that impaired filling of the heart, perhaps due to "stiffness" of the heart muscle itself, critically underlies HFpEF. There is currently no clinical technique for measuring heart muscle (myocardial) stiffness; the very definition of "myocardial stiffness" remains poorly established. Consequently, the ability to study the mechanisms that underlie HFpEF is virtually non-existent, and limited treatment options will persist without significant advances. The objective of this project is to use an Equilibrium-Material-Stability (EMS) framework that couples patient-specific clinical MRI and heart pressure data in a computational model of the heart to diagnose changes in myocardial stiffness. The central hypothesis is that the new EMS framework for understanding the mechanisms of diastolic dysfunction in HFpEF will be more sensitive and outperform currently available approaches.

Detailed description: The study has three aims. The first aim of the project is to refine MRI techniques using "free-breathing" versus "breath-holding" measurements. Twenty-five normal volunteers will undergo MRI to refine "free-breathing" cardiac imaging and enable construction of patient-specific computer models of the heart. The second aim of the project is to validate and test the myocardial stiffness evaluation framework derived through the first objective in human subjects. Twenty-five normal volunteers will undergo MRI and the data from these images will be compared to specially constructed 3D printed models of the heart, enabling refinement of the EMS framework to separate structural stiffness from material stiffness. The third aim of the project is to measure changes in myocardial stiffness in patients with HFpEF. Thirty-three subjects with current diagnostic criteria for HFpEF will be evaluated at baseline and at six months to evaluate myocardial stiffness and cardiac MRI biomarkers. Specifically, this aim will establish the diagnostic sensitivity of the EMS framework with comparison to cardiac MRI biomarkers of increased stiffness, thereby providing mechanistic insight to one critical underlying cause of HFpEF.

Eligibility criteria: Inclusion Criteria:

Healthy volunteers

1. Healthy adults

Patients with Heart Failure with Preserved Ejection Fraction

1. Patient scheduled for catheterization at UCLA Medical Center
2. Ejection fraction \>/= 50%
3. Signs and symptoms of heart failure
4. Excluded other potential non-cardiac etiologies of heart failure

Exclusion Criteria:

Healthy volunteers

1. Known medical condition that impacts heart health
2. Contraindications to MRI (e.g., pacemaker/ICD, or claustrophobia)

Patients with Heart Failure with Preserved Ejection Fraction

Exclusion Criteria:

1. Contraindications to MRI (e.g., pacemaker/ICD, or claustrophobia)
2. Prior MI or history of PCI/CABG
3. Worse than mild valvular disease
4. Any indication for ICD implantation
5. Contraindication to MRI contrast agents or eGRF \<30 ml/min/1.73m2 or MRI exams (e.g., pacemaker/ICD or claustrophobia).
6. Atrial fibrillation or unstable cardiac rhythm

Primary outcomes:
measure: The sensitivity of the EMS framework with comparison to cardiac MRI biomarkers of increased stiffness, thereby providing mechanistic insight to one critical underlying cause of HFpEF.
timeFrame: Five years
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of California Los Angeles
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Daniel J Ennis, PhD
role: PRINCIPAL_INVESTIGATOR
References: